PBAC's latest decision on Inactivated trivalent influenza vaccine (split virion): Recommended (2018). Considered for Active immunisation against influenza disease caused by influenza virus subtypes A and type B for use in persons 65 years and older.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Adults aged ≥65 years eligible for free influenza vaccines through the National Immunisation Program.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
Registry
Primary endpoint
Surrogate
Comparator
quadrivalent inactivated influenza vaccine (QIV)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Proposed price equal to nationally negotiated price of QIV comparator.